These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 11739444

  • 1. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
    [Abstract] [Full Text] [Related]

  • 3. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 4. The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
    Nielsen S, Møller N, Pedersen SB, Christiansen JS, Jørgensen JO.
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3274-8. PubMed ID: 12107236
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
    Nielsen S, Møller N, Christiansen JS, Jørgensen JO.
    Diabetes; 2001 Oct; 50(10):2301-8. PubMed ID: 11574412
    [Abstract] [Full Text] [Related]

  • 6. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
    Pontiroli AE, Lanzi R, Monti LD, Pozza G.
    J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
    [Abstract] [Full Text] [Related]

  • 7. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 8. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
    Lanzi R, Manzoni MF, Andreotti AC, Malighetti ME, Bianchi E, Sereni LP, Caumo A, Luzi L, Pontiroli AE.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
    [Abstract] [Full Text] [Related]

  • 9. Mediation of the hepatic effects of growth hormone by its lipolytic activity.
    Piatti PM, Monti LD, Caumo A, Conti M, Magni F, Galli-Kienle M, Fochesato E, Pizzini A, Baldi L, Valsecchi G, Pontiroli AE.
    J Clin Endocrinol Metab; 1999 May; 84(5):1658-63. PubMed ID: 10323396
    [Abstract] [Full Text] [Related]

  • 10. Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.
    Vestergaard ET, Hansen TK, Nielsen S, Moller N, Christiansen JS, Jorgensen JO.
    Eur J Endocrinol; 2005 Oct; 153(4):545-9. PubMed ID: 16189176
    [Abstract] [Full Text] [Related]

  • 11. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 12. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M, Muzj G, Leoni F, Romualdi D, Belosi C, Cento RM, Lanzone A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics.
    Krag MB, Gormsen LC, Guo Z, Christiansen JS, Jensen MD, Nielsen S, Jørgensen JO.
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E920-7. PubMed ID: 17132823
    [Abstract] [Full Text] [Related]

  • 14. The control on growth hormone release by free fatty acids is maintained in acromegaly.
    Lanzi R, Losa M, Mignogna G, Caumo A, Pontiroli AE.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1234-8. PubMed ID: 10199760
    [Abstract] [Full Text] [Related]

  • 15. Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man.
    Ekstrand A, Saloranta C, Ahonen J, Grönhagen-Riska C, Groop LC.
    Metabolism; 1992 Jul; 41(7):692-7. PubMed ID: 1619986
    [Abstract] [Full Text] [Related]

  • 16. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Jimenez LM, Astorga R, Fernandez-Lopez I, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
    [Abstract] [Full Text] [Related]

  • 17. Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients.
    Nielsen S, Jørgensen JO, Hartmund T, Nørrelund H, Nair KS, Christiansen JS, Møller N.
    Growth Horm IGF Res; 2002 Dec; 12(6):425-33. PubMed ID: 12423628
    [Abstract] [Full Text] [Related]

  • 18. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
    Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
    [Abstract] [Full Text] [Related]

  • 19. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H, Stanley TL, Suresh C, De Sousa-Coelho AL, Frontera WR, Syu S, Braun LR, Looby SE, Feldpausch MN, Torriani M, Lee H, Patti ME, Grinspoon SK.
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
    [Abstract] [Full Text] [Related]

  • 20. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.